TNFRSF1A and esophageal squamous cell carcinoma: Further treatment of ESCC cells silencing METTL3 or ATXN2 with the protein synthesis inhibitor cycloheximide resulted in no difference in half-life for TNFR1 compared with control cells (Figure S3E).